Elezanumab - AbbVie

Drug Profile

Elezanumab - AbbVie

Alternative Names: ABT-555

Latest Information Update: 29 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AbbVie
  • Class Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Immunomodulators; Myelin protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 10 Oct 2018 Pharmacokinetic and adverse events from a phase I trial in Multiple sclerosis presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
  • 24 Jun 2018 Biomarkers information updated
  • 20 Apr 2018 AbbVie completes a phase I trial in Multiple sclerosis in USA (IV-infusion) (NCT02601885)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top